Aragon obtains $42M in funding for cancer drug development

03/7/2012 | Genetic Engineering & Biotechnology News

Aragon Pharmaceuticals secured $42 million in a Series C funding round headed by new investor Topspin Fund. The money will be used to advance the development of Aragon's early clinical and preclinical androgen receptor- and estrogen receptor-targeting drugs for certain prostate and breast cancers.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care